Donanemab Study: Impact on Alzheimer’s Progression and Potential Risks
2023-09-26 12:00:00 The donanemab study was structured similarly. Just over 1,700 test subjects with early signs of Alzheimer’s took part in it and received either the experimental therapy or a dummy drug every two weeks for 18 months. Across the entire patient group, the CDR-SB score fell by 29 percent less in those treated with … Read more